FemPulse Announces Issuance of Patents in China and Australia
January 06, 2020 09:00 ET
|
FemPulse
MINNEAPOLIS, Jan. 06, 2020 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Secures Equity Financing to Finalize Development of Proprietary Bioelectronic Device for Treatment of Overactive Bladder in Women
December 05, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Announces Enrollment of First Participant in Clinical Study for Personalized Treatment of Overactive Bladder (OAB) in Women
July 15, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, July 15, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse to Participate in Panel Discussion at the 2019 Bioelectronic Medicine Forum
March 26, 2019 09:01 ET
|
FemPulse
MINNEAPOLIS, March 26, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Appoints Dr. Robert Kieval as Chief Scientific and Clinical Officer
March 05, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, March 05, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...
FemPulse Announces Enrollment in Multi-Center EVANESCE-OAB Study
February 25, 2019 09:00 ET
|
FemPulse
MINNEAPOLIS, Feb. 25, 2019 (GLOBE NEWSWIRE) -- FemPulse Corporation (FemPulse), a private, clinical-stage bioelectronic medicine company developing a novel therapy for the personalized treatment of...